Surgery Partners, Inc. (NASDAQ:SGRY – Get Free Report) CFO David T. Doherty sold 6,733 shares of Surgery Partners stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $24.02, for a total transaction of $161,726.66. Following the completion of the sale, the chief financial officer now directly owns 150,868 shares in the company, valued at $3,623,849.36. This trade represents a 4.27 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Surgery Partners Stock Performance
Shares of NASDAQ SGRY opened at $23.60 on Friday. The stock’s 50-day moving average is $23.58 and its 200 day moving average is $26.08. The stock has a market cap of $3.01 billion, a price-to-earnings ratio of -49.17, a P/E/G ratio of 19.21 and a beta of 2.73. Surgery Partners, Inc. has a 1-year low of $19.50 and a 1-year high of $33.97. The company has a current ratio of 1.80, a quick ratio of 1.66 and a debt-to-equity ratio of 0.99.
Surgery Partners (NASDAQ:SGRY – Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The company reported $0.39 EPS for the quarter, topping the consensus estimate of $0.38 by $0.01. The firm had revenue of $864.40 million for the quarter, compared to the consensus estimate of $828.09 million. Surgery Partners had a negative net margin of 2.03% and a positive return on equity of 2.85%. On average, sell-side analysts anticipate that Surgery Partners, Inc. will post 0.67 EPS for the current fiscal year.
Institutional Trading of Surgery Partners
Wall Street Analysts Forecast Growth
Several equities research analysts have commented on the stock. Bank of America started coverage on shares of Surgery Partners in a report on Monday, December 16th. They set a “buy” rating and a $30.00 price objective on the stock. JPMorgan Chase & Co. decreased their price target on shares of Surgery Partners from $38.00 to $28.00 and set a “neutral” rating on the stock in a report on Tuesday, December 3rd. Royal Bank of Canada dropped their price objective on Surgery Partners from $49.00 to $35.00 and set an “outperform” rating for the company in a research note on Wednesday, November 20th. Finally, Macquarie decreased their target price on Surgery Partners from $34.00 to $33.00 and set an “outperform” rating on the stock in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $36.63.
Check Out Our Latest Analysis on SGRY
About Surgery Partners
Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.
Read More
- Five stocks we like better than Surgery Partners
- Why Invest in 5G? How to Invest in 5G Stocks
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- Trading Halts Explained
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- Short Selling: How to Short a Stock
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for Surgery Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surgery Partners and related companies with MarketBeat.com's FREE daily email newsletter.